Recombinant Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] - BSA and Azide free (ab221924)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP1978Y] to COX2 / Cyclooxygenase 2 - BSA and Azide free
- Suitable for: WB
- Knockout validated
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] - BSA and Azide free
See all COX2 / Cyclooxygenase 2 primary antibodies -
Description
Rabbit monoclonal [EP1978Y] to COX2 / Cyclooxygenase 2 - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab213704) -
Positive control
- Raw264.7 cell lysate + LPS. Flow Cyt: HeLa cells
-
General notes
ab221924 is the carrier-free version of ab62331.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Dissociation constant (KD)
KD = 1.01 x 10 -11 M Learn more about KD -
Storage buffer
pH: 7.20
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP1978Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Immunizing Peptide (Blocking)
-
Isotype control
-
KO cell lines
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab221924 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Detects a band of approximately 72 kDa (predicted molecular weight: 69 kDa).Can be blocked with COX2 / Cyclooxygenase 2 peptide (ab213704).
|
Notes |
---|
WB
Use at an assay dependent concentration. Detects a band of approximately 72 kDa (predicted molecular weight: 69 kDa).Can be blocked with COX2 / Cyclooxygenase 2 peptide (ab213704). |
Target
-
Function
Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity. -
Pathway
Lipid metabolism; prostaglandin biosynthesis. -
Sequence similarities
Belongs to the prostaglandin G/H synthase family.
Contains 1 EGF-like domain. -
Post-translational
modificationsS-nitrosylation by NOS2 (iNOS) activates enzme activity. S-nitrosylation may take place on different Cys residues in addition to Cys-561. -
Cellular localization
Microsome membrane. Endoplasmic reticulum membrane. - Information by UniProt
-
Database links
- Entrez Gene: 5743 Human
- Entrez Gene: 19225 Mouse
- Omim: 600262 Human
- SwissProt: P35354 Human
- SwissProt: Q05769 Mouse
- Unigene: 196384 Human
- Unigene: 292547 Mouse
-
Alternative names
- COX 2 antibody
- COX-2 antibody
- COX2 antibody
see all
Images
-
All lanes : Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] (ab62331) at 1/500 dilution
Lane 1 : Wild-type A549 cell lysate
Lane 2 : PTGS2 knockout A549 cell lysate
Lane 3 : U-87 MG cell lysate
Lane 4 : MOLT-4 cell lysate
Lane 5 : Wild-type Hela ab255929 cell lysate
Lane 6 : PTGS2 knockout HeLa ab255524 cell lysate
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
Predicted band size: 69 kDa
Observed band size: 75 kDa why is the actual band size different from the predicted?False colour image of Western blot: Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] staining at 1/500 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab62331 was shown to bind specifically to COX2 / Cyclooxygenase 2. A band was observed at 75 kDa in wild-type A549 cell lysates with no signal observed at this size in PTGS2 knockout cell line ab280802 (knockout cell lysate ab283825). The band at 65 kDa is a unknown protein as a result of non-specific binding of the antibody. To generate this image, wild-type and PTGS2 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
-
All lanes : Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] (ab62331) at 1/1000 dilution (purified)
Lane 1 : Untreated Raw 264.7 cell lysate
Lane 2 : Raw 264.7 treated with LPS
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-conjugated goat anti-rabbit IgG (H+L) at 1/50000 dilution
Predicted band size: 69 kDa
Observed band size: 72 kDa why is the actual band size different from the predicted?This data was developed using ab62331, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] (ab62331) at 1/1000 dilution (Purified)
Lane 1 : HCT 116 (human colorectal carcinoma cell line) whole cell lysate
Lane 2 : MCF7 (human breast adenocarcinoma cell line) whole cell lysate
Lane 3 : U-87 MG (human glioblastoma-astrocytoma epithelial cell line) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/200000 dilution
Predicted band size: 69 kDa
Observed band size: 72 kDa why is the actual band size different from the predicted?This data was developed using ab62331, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST. Exposure times:
Lanes 1-2: 5.5 seconds
Lane 3: 3.25 seconds
We are unsure as to the identity of the extra band in HCT 116 and MCF7.
The expression profile observed in HCT 116 and MCF7 are consistent with the literatures (PMID: 14739610, 24325753, 16997132).
Negative control: HCT 116 (PMID: 14739610) and MCF7 (PMID: 24325753, 16997132).
-
Anti-COX2 / Cyclooxygenase 2 antibody [EP1978Y] (ab62331) at 1/500 dilution (unpurified) + Raw264.7 cell lysate (10ug) + LPS
Secondary
Goat anti-Rabbit HRP conjugated at 1/2000 dilution
Predicted band size: 69 kDa
Observed band size: 72 kDa why is the actual band size different from the predicted?This data was developed using ab62331, the same antibody clone in a different buffer formulation.
Protocols
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (8)
ab221924 has been referenced in 8 publications.
- Khalesi M et al. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk. Int J Dermatol 55:1096-105 (2016). PubMed: 27126210
- Hsu CK et al. Sphingosine-1-phosphate mediates COX-2 expression and PGE2 /IL-6 secretion via c-Src-dependent AP-1 activation. J Cell Physiol 230:702-15 (2015). PubMed: 25201048
- Zhao L et al. Effect of Chronic Psychological Stress on Liver Metastasis of Colon Cancer in Mice. PLoS One 10:e0139978 (2015). PubMed: 26444281
- Lowin T et al. Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther 17:321 (2015). WB, ICC/IF . PubMed: 26567045
- Hayashi G et al. Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. Hum Mol Genet N/A:N/A (2014). WB ; Human . PubMed: 25104852
- Chabbi-Achengli Y et al. Serotonin 2B Receptor (5-HT2B R) Signals through Prostacyclin and PPAR-ß/d in Osteoblasts. PLoS One 8:e75783 (2013). WB ; Human . PubMed: 24069449
- Hennessy BT et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6:129-51 (2010). Dot blot ; Human . PubMed: 21691416
- Kim WY et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) 1:577-87 (2008). PubMed: 19139008